2024欧洲肿瘤学会（ESMO 2024）年会即将来袭，此次会议将于欧洲中部夏令时间（CET）9月13日-17日在西班牙巴塞罗那举行。
近日，ESMO大会官方已公布除Late-breaking abstracts（LBA）外的所有口头摘要题目及作者信息。【肿瘤资讯】特别整理本次公布的泌尿肿瘤相关专场重磅研究（主要包含MO：mini oral；O：oral）标题，以飨读者。
Proffered paper session 1: 泌尿肿瘤, 非前列腺癌
本专场有3个LBA摘要待确认（TBC）
专场时间：2024年9月13日，14:00 - 15:30
专场主席：Dana Rathkopf (New York, United States of America, NY)，Gerhardt Attard (London, United Kingdom)
专场地点：Granada Auditorium - Hall 6
1959O
BL-B01D1, an EGFR x HER3 Bispecific Antibody-drug Conjugate (ADC), in Patients with Locally Advanced or Metastatic Urothelial Carcinoma (UC)
BL-B 01 D1，EGFR x HER 3双特异性抗体-药物偶联物（ADC），用于局部晚期或转移性尿路上皮癌（UC）患者
讲者：叶定伟(上海, 中国)
1690O
NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a Phase 1/2 study
NKT 2152，一种新型口服HIF-2α抑制剂，用于既往经治疗的晚期肾透明细胞癌（accRCC）患者：一项I/II期研究的初步结果
讲者：Eric Jonasch (Houston, United States of America, TX)
Proffered paper session 2 :泌尿肿瘤, 非前列腺癌
本专场有4个LBA摘要待确认（TBC）
专场时间：2024年9月16日，08:30-10:00
专场地点：Sevilla Auditorium - Hall 2
1960O
Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial
基于连续循环肿瘤DNA（ctDNA）检测识别可能从早期膀胱切除术后免疫治疗中受益的膀胱癌患者的初步结果：来自TOMBOLA试验的初步结果
讲者：Jorgen Bjerggaard Jensen (Aarhus, Denmark)
1961O
Nivolumab plus chemoradiotherapy in patients with non-metastatic muscle-invasive bladder cancer (nmMIBC), not undergoing cystectomy: a phase II, randomized study by the Hellenic GU Cancer Group.
纳武利尤单抗联合放化疗治疗未进行膀胱切除的非转移性肌层浸润性膀胱癌患者：由希腊泌尿生殖系统癌症组织进行的II期随机研究
讲者：Andromachi Kougioumtzopoulou (Haidari, Greece)
1962O
Health-related quality of life from the CheckMate 901 trial of nivolumab as first-line therapy for unresectable or metastatic urothelial carcinoma
CheckMate 901试验：纳武利尤单抗作为不可切除或转移性尿路上皮癌一线治疗的健康相关生活质量
讲者：Jens Bedke (Stuttgart, Germany)
Proffered paper session: 泌尿肿瘤, 前列腺癌
本专场有4个LBA摘要待确认（TBC）
专场时间：2024年9月15日，14:45-16:15
专场地点：Valencia Auditorium - Hall 5
Mini oral session: 泌尿肿瘤, 前列腺癌
本专场有5个LBA摘要待确认（TBC）
专场时间：2024年9月16日，10:15-11:45
专场地点：Madrid Auditorium - Hall 2
1595MO
Phenotypic and genomic characterization of de novo metastatic prostate cancer: an ancillary study of the PEACE-1 phase 3 trial.
原发转移性前列腺癌的表型和基因组特征：PEACE-1第3期试验的辅助研究
讲者：Cedric Pobel (Villejuif, Cedex, France)
1596MO
Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): an ancillary study of the STAMPEDE docetaxel trials
Decipher mRNA评分用于预测在开始雄激素剥夺治疗（ADT）时，对晚期前列腺癌患者从多西他赛中获得生存益处：STAMPEDE多西他赛试验的辅助研究
讲者：Emily Grist (London, United Kingdom
1597MO
Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
BMS-986365（CC-94676），一种双重雄激素受体（AR）配体导向降解剂和拮抗剂，在经过大量预处理的转移性去势抵抗性前列腺癌患者中的临床活性
讲者：Dana Rathkopf (New York, United States of America, NY)
Mini oral session: 泌尿肿瘤, 非前列腺癌
本专场有4个LBA摘要待确认（TBC）
专场时间：2024年9月16日，08:30-10:00
专场地点：Bilbao Auditorium - Hall 2
1963MO
JCOG1019: An Open-label, Non-inferiority, Randomised Phase 3 Study Comparing the Effectiveness of Watchful Waiting (WW) and Intravesical Bacillus Calmette-Guérin (BCG) in Patients (Pts) with High-grade pT1 (HGT1) Bladder Cancer with pT0 on the 2nd Transurethral Resection (TUR) Specimen
JCOG1019：一项开放标签、非劣效性、随机的3期研究，比较了在第二程经尿道电切术（TUR）标本中pT0的高级别pT1（HGT1）膀胱癌患者中，观察等待与膀胱内卡介苗治疗的疗效
讲者：Hiroshi Kitamura (Toyama, Japan)
1964MO
Alliance A031501: AMBASSADOR Study of Adjuvant Pembrolizumab (Pembro) in Muscle-Invasive Urothelial Carcinoma (MIUC) vs Observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution
Alliance A031501：AMBASSADOR研究中肌层浸润性尿路上皮癌（MIUC）患者辅助帕博利珠单抗治疗 vs.观察：延长随访的无病生存（DFS）结果和转移性疾病复发分布
讲者：Andrea B. Apolo (Bethesda, United States of America)
1965MO
Phase 2 study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
Futibatinib联合帕博利珠单抗在晚期/转移性尿路上皮癌患者中的2期研究：疗效和安全性的最终分析
讲者：Vadim S. Koshkin (San Francisco, United States of America)
1966MO
EV-302: Exploratory Analysis of Nectin-4 Expression and Response to 1L Enfortumab Vedotin (EV) + Pembrolizumab (P) in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
EV-302：既往未经治疗的局部晚期或转移性尿路上皮癌（la/mUC）中Nectin-4表达和一线 Enfortumab Vedotin（EV）+帕博利珠单抗（P）应答的探索性分析
讲者：Thomas B. Powles (London, United Kingdom)
1967MO
Preliminary Efficacy And Safety Of Disitamab Vedotin (DV) With Pembrolizumab (P) In Treatment (Tx)-Naive HER2-Expressing, Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): RC48G001 Cohort C
Disitamab Vedotin（DV）联合帕博利珠单抗（P）在未经治疗的HER2表达的局部晚期或转移性尿路上皮癌（la/mUC）中的初步疗效和安全性：RC48G001队列C
讲者：Matthew D. Galsky (New York, United States of America)
如有遗漏，敬请留言补充！
排版编辑：肿瘤资讯-CY
苏公网安备32059002004080号
